Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Li Zhang et al.|The Lancet Oncology|2011Cited by 4.1k
Cisplatin resistance in lung cancer is mediated by <italic>MACC1</italic> expression through PI3K/AKT signaling pathway activationQiang Zhang, Changli Wang|Acta Biochimica et Biophysica Sinica|2018Cited by 17
Validation of EORTC QLQ-LC43 for Chinese patients with lung cancerLei Zhang, Changli Wang, Yanjun Su et al.|Lung Cancer|2014Cited by 15
Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.Fenlai Tan, Yan Sun, Aiqin Gu et al.|Journal of Clinical Oncology|2013Cited by 5
Iconographies supplémentaires de l'article : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Yi‐Long Wu et al.|Unknown|2011Cited by 5